The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis?
3 - 5
Mult Scler Relat Disord
MetadataShow full item record
If it is not feasible to develop licensed drugs to the stage that they can actually be prescribed for a new indication, can we justify, either ethically or economically, the undertaking of proof-of-concept studies using off-patent medications? Without a financial incentive it is very difficult to repurpose off patent drugs for a new indication. Therefore, we need a political solution to allow the repurposing of off-patent drugs by other stakeholders or Big Pharma.
AuthorsGiovannoni, G; Baker, D; Schmierer, K
- College Publications